# Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia

> **NCT00142116** · PHASE2 · COMPLETED · sponsor: **Steven P. Treon, MD, PhD** · enrollment: 25 (actual)

## Conditions studied

- Waldenstrom's Macroglobulinemia
- Lymphoplasmacytic Lymphoma

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00142116
- **Lead sponsor:** Steven P. Treon, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2004-02
- **Final completion:** 2008-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2014-06-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00142116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00142116, "Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00142116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*